Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.

Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C.

BMC Genomics. 2008 May 22;9:239. doi: 10.1186/1471-2164-9-239.

2.

Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.

Kok M, Koornstra RH, Mook S, Hauptmann M, Fles R, Jansen MP, Berns EM, Linn SC, Van 't Veer LJ.

Breast. 2012 Dec;21(6):769-78. doi: 10.1016/j.breast.2012.04.010. Epub 2012 Jun 26.

PMID:
22738860
3.

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.

Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C.

Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10208-13. doi: 10.1073/pnas.0907011107. Epub 2010 May 17.

4.

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.

Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly C, Müller V, Schmidt S, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L.

Breast Cancer Res. 2013;15(5):R86.

5.

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.

Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM.

Breast Cancer Res Treat. 2009 Jan;113(2):275-83. doi: 10.1007/s10549-008-9939-y. Epub 2008 Mar 4.

PMID:
18311582
6.

A candidate molecular signature associated with tamoxifen failure in primary breast cancer.

Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.

Breast Cancer Res. 2008;10(5):R88. doi: 10.1186/bcr2158. Epub 2008 Oct 17.

7.

Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.

Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA.

Breast Cancer Res Treat. 2012 Sep;135(2):415-32. doi: 10.1007/s10549-012-2164-8. Epub 2012 Jul 24.

8.

A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.

Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, González-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL.

Clin Cancer Res. 2011 Apr 1;17(7):2024-34. doi: 10.1158/1078-0432.CCR-10-2567. Epub 2011 Feb 23.

9.

Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.

Yamashita H, Yando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H.

Breast Cancer. 2006;13(1):74-83.

10.

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.

Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM.

Ann Oncol. 2012 Nov;23(11):2866-73. doi: 10.1093/annonc/mds080. Epub 2012 Apr 24.

11.

A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.

Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, Darbon JM.

Clin Cancer Res. 2008 Mar 15;14(6):1744-52. doi: 10.1158/1078-0432.CCR-07-1833.

12.

A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen.

Kerr DA 2nd, Wittliff JL.

Horm Cancer. 2011 Oct;2(5):261-71. doi: 10.1007/s12672-011-0080-8.

PMID:
21826535
13.

HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.

Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO.

Breast Cancer Res Treat. 2008 May;109(2):351-7. Epub 2007 Jul 18.

PMID:
17636399
14.

Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.

Yu KD, Di GH, Wu J, Lu JS, Shen KW, Liu GY, Shen ZZ, Shao ZM.

J Cancer Res Clin Oncol. 2008 Dec;134(12):1347-54. doi: 10.1007/s00432-008-0414-2. Epub 2008 May 17.

PMID:
18488249
15.

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.

Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R, Baum M.

Ann Oncol. 2006 May;17(5):818-26. Epub 2006 Feb 23.

PMID:
16497822
16.

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.

Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, Fumagalli D, Taniyama Y, Lee A, Reilly ML, Vogel VG, McCaskill-Stevens W, Ford LG, Geyer CE Jr, Wickerham DL, Wolmark N, Paik S.

J Clin Oncol. 2011 Nov 1;29(31):4160-7. doi: 10.1200/JCO.2010.32.9615. Epub 2011 Sep 26.

17.

A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation.

Zhou X, Li B, Zhang Y, Gu Y, Chen B, Shi T, Ao L, Li P, Li S, Liu C, Guo Z.

Breast Cancer Res Treat. 2013 Dec;142(3):505-14. doi: 10.1007/s10549-013-2767-8. Epub 2013 Nov 20.

PMID:
24253811
18.

Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.

Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L.

Clin Cancer Res. 2007 Apr 1;13(7):2061-7.

19.

Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.

Meattini I, Livi L, Saieva C, Franceschini D, Scotti V, Mangoni M, Loi M, Di Brina L, Zei G, Bonomo P, Greto D, Gelain E, Nori J, Sanchez LJ, Orzalesi L, Bianchi S, Biti G.

Clin Breast Cancer. 2013 Aug;13(4):247-53. doi: 10.1016/j.clbc.2013.02.005. Epub 2013 May 15.

PMID:
23684167
20.

An iron regulatory gene signature predicts outcome in breast cancer.

Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D'Agostino R Jr, Torti SV, Torti FM.

Cancer Res. 2011 Nov 1;71(21):6728-37. doi: 10.1158/0008-5472.CAN-11-1870. Epub 2011 Aug 29.

Supplemental Content

Support Center